Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07828249) titled 'Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma' on Sept. 3.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Centre Leon Berard

Condition: Metastatic Clear Cell Renal Cell Carcinoma

Intervention: Drug: 161Tb-PSMA-1 (radiopharmaceutical)

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: November 2026

Target Sample Size: 26

Countries of Recruitment: France

To know more, visit https://clinic...